Literature DB >> 18496673

Partial agonism at the human alpha(2A)-autoreceptor: role of binding duration.

M Hoeren1, B Brawek, M Mantovani, M Löffler, M Steffens, V van Velthoven, T J Feuerstein.   

Abstract

Temperature-induced changes of affinity and efficacy of the alpha2-adrenoceptor full agonist UK14,304 and the partial agonists clonidine and guanfacine were investigated to elucidate the mechanism of partial agonism at the terminal alpha2-autoreceptor. The effect of temperature on the efficacy of the substances was tested in 3H-noradrenaline release experiments at 37 degrees C and at room temperature. Human neocortical slices were prelabeled with 3H-noradrenaline, superfused, and stimulated electrically under autoinhibition-free conditions. Furthermore, saturation binding experiments with human neocortical synaptosomes were performed at 37 degrees C and 17 degrees C to evaluate the influence of temperature on the affinity of 3H-clonidine and 3H-UK14,304. Temperature-induced changes of the association and dissociation rate constants of 3H-UK14,304 and 3H-clonidine were assessed in corresponding kinetic binding experiments. Our experiments reveal that clonidine and guanfacine lose efficacy when the temperature is lowered, whereas no change was noted for the full agonist UK14,304. Moreover, the affinity of clonidine and guanfacine was shown to decrease at lower temperature. Kinetic experiments indicated that the loss of affinity observed for 3H-clonidine at 17 degrees C is due to a marked reduction of the association rate. The loss of efficacy of the partial agonists is most likely related to the short binding duration; partial agonists do not bind long enough to the receptor to mediate a maximum response. The discrepancy between the time required to elicit a maximum response and the actual binding time may be greater for partial agonists at lower temperatures, thus, causing the intrinsic activity to decline.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18496673     DOI: 10.1007/s00210-008-0295-6

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  25 in total

Review 1.  Radioligand saturation binding experiments over large concentration ranges.

Authors:  D B Bylund; L C Murrin
Journal:  Life Sci       Date:  2000-11-03       Impact factor: 5.037

2.  Characterization of the alpha(2)-adrenoceptor subtype, which functions as alpha(2)-autoreceptor in human neocortex.

Authors:  T J Feuerstein; B Huber; J Vetter; H Aranda; V Van Velthoven; N Limberger
Journal:  J Pharmacol Exp Ther       Date:  2000-07       Impact factor: 4.030

Review 3.  Principles: receptor theory in pharmacology.

Authors:  Terry Kenakin
Journal:  Trends Pharmacol Sci       Date:  2004-04       Impact factor: 14.819

4.  Gs activation is time-limiting in initiating receptor-mediated signaling.

Authors:  Peter Hein; Francesca Rochais; Carsten Hoffmann; Sandra Dorsch; Viacheslav O Nikolaev; Stefan Engelhardt; Catherine H Berlot; Martin J Lohse; Moritz Bünemann
Journal:  J Biol Chem       Date:  2006-09-08       Impact factor: 5.157

Review 5.  Drug efficacy at G protein-coupled receptors.

Authors:  Terry Kenakin
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002       Impact factor: 13.820

6.  Binding thermodynamics and intrinsic activity of adenosine A1 receptor ligands.

Authors:  A Dalpiaz; A Scatturin; K Varani; R Pecoraro; B Pavan; P A Borea
Journal:  Life Sci       Date:  2000-08-11       Impact factor: 5.037

7.  Interactions of full and partial agonists with HT29 cell alpha 2-adrenoceptor: comparative study of [3H]UK-14,304 and [3H]clonidine binding.

Authors:  H Paris; J Galitzky; J M Senard
Journal:  Mol Pharmacol       Date:  1989-03       Impact factor: 4.436

8.  Sarcoplasmic reticulum from rabbit and winter flounder: temperature-dependence of protein conformation and lipid motion.

Authors:  N Vrbjar; K T Kean; A Szabo; L Senak; R Mendelsohn; K M Keough
Journal:  Biochim Biophys Acta       Date:  1992-06-11

Review 9.  Evolving concepts of partial agonism. The beta-adrenergic receptor as a paradigm.

Authors:  J R Jasper; P A Insel
Journal:  Biochem Pharmacol       Date:  1992-01-22       Impact factor: 5.858

10.  Adrenergic receptors in frontal cortex in human brain.

Authors:  R Cash; R Raisman; M Ruberg; Y Agid
Journal:  Eur J Pharmacol       Date:  1985-02-05       Impact factor: 4.432

View more
  3 in total

1.  Functional efficacy of adenosine A₂A receptor agonists is positively correlated to their receptor residence time.

Authors:  Dong Guo; Thea Mulder-Krieger; Adriaan P IJzerman; Laura H Heitman
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

2.  A2AR Binding Kinetics in the Ligand Depletion Regime.

Authors:  Patrick M McNeely; Andrea N Naranjo; Kimberly Forsten-Williams; Anne Skaja Robinson
Journal:  SLAS Discov       Date:  2016-09-27       Impact factor: 3.341

3.  A Comparison of the Anorectic Effect and Safety of the Alpha2-Adrenoceptor Ligands Guanfacine and Yohimbine in Rats with Diet-Induced Obesity.

Authors:  Magdalena Dudek; Joanna Knutelska; Marek Bednarski; Leszek Nowiński; Małgorzata Zygmunt; Barbara Mordyl; Monika Głuch-Lutwin; Grzegorz Kazek; Jacek Sapa; Karolina Pytka
Journal:  PLoS One       Date:  2015-10-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.